At the pulse of heart disease

We are pioneers in the discovery and development of non-coding RNA-based therapeutics designed to address the root causes of heart disease.

A plastic red heart in an indicated rib cage, on a light background

Mode of Action

The video illustrates how CDR132L operates in cardiac cells to reverse adverse cardiac remodeling and restore normal cellular functions.

CDR132L is currently being evaluated in HF-REVERT Phase 2 Clinical Study in heart failure patients after myocardial infarction.


Oxford’s Global Biologics 2024 Congress
Keystone Symposia on Molecular & Cellular Biology
German Biotech Days 2024